FATE’s FT819 CAR T shows promising early lupus nephritis efficacy
Fate’s phase II trial of FT819 in lupus nephritis is progressing, supported by a scalable master cell bank approach. The program targets a 30%-40% CRR, with key data readouts expected by early next year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.